Law360, New York (May 05, 2005, 12:00 AM ET) -- Drug maker Andrx Corp. has entered into a marketing rights agreement with Amphastar Pharmaceuticals for a generic version of Sanofi-Aventis’ Lovenox, a treatment for deep vein thrombosis.
Amphastar's generic version is currently the subject of a patent infringement lawsuit brought by Aventis and is under a 30-month stay that expires in February 2006.
In December, Aventis’ bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally won approval from the U.S. Patent and Trademark office.
The USPTO previously rejected two attempts...
Andrx, Amphastar Pen Deal For Generic Lovenox
To view the full article, take a free trial now.
